Insights & Resources

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The U.S. Department of the Treasury and Internal Revenue Service have issued long-awaited guidance for the 45Z Clean Fuel Production Credit.

KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.

Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

The energy sector has been marked by its market volatility lately. CEOs in the industry can use established ESG principles to create sustainable business practices.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Federal and state governments issued fuel tax relief after Hurricane Helene, including IRS dyed diesel penalty waivers, temporary licensing and IFTA suspensions.

A recent U.S. complaint highlights the growing need for health care systems to ensure physician compensation aligns with fair market value to avoid compliance risks.

Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.

The instances of urgent care clinic visits have returned to pre-pandemic levels, but COVID-related services still make up a large percentage of the total volume.